NOVEL THERAPIES IN THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

被引：0

作者：

Carlo-Stella, C. ^{[1
,2
]}

Calabretta, E. ^{[1
,2
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[2] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Dept Oncol & Hematol, Milan, Italy

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

SINGLE-ARM; OPEN-LABEL; MULTICENTER;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：201 / 202

页数：2

共 10 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial [J].

Caimi, Paolo F. ;

Ai, Weiyun ;

Alderuccio, Juan Pablo ;

Ardeshna, Kirit M. ;

Hamadani, Mehdi ;

Hess, Brian ;

Kahl, Brad S. ;

Radford, John ;

Solh, Melhem ;

Stathis, Anastasios ;

Zinzani, Pier Luigi ;

Havenith, Karin ;

Feingold, Jay ;

He, Shui ;

Qin, Yajuan ;

Ungar, David ;

Zhang, Xiaoyan ;

Carlo-Stella, Carmelo .

LANCET ONCOLOGY, 2021, 22 (06) :790-800

[3] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[4] Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial [J].

Hutchings, Martin ;

Morschhauser, Franck ;

Iacoboni, Gloria ;

Carlo-Stella, Carmelo ;

Offner, Fritz C. ;

Sureda, Anna ;

Salles, Gilles ;

Martinez-Lopez, Joaquin ;

Crump, Michael ;

Thomas, Denise N. ;

Morcos, Peter N. ;

Ferlini, Cristiano ;

Broeske, Ann-Marie E. ;

Belousov, Anton ;

Bacac, Marina ;

Dimier, Natalie ;

Carlile, David J. ;

Lundberg, Linda ;

Perez-Callejo, David ;

Umana, Pablo ;

Moore, Tom ;

Weisser, Martin ;

Dickinson, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1959-+

[5]

Kalakonda N, 2020, LANCET HAEMATOL, V7, pE509

[6] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial [J].

Locke, Frederick L. ;

Ghobadi, Armin ;

Jacobson, Caron A. ;

Miklos, David B. ;

Lekakis, Lazaros J. ;

Oluwole, Olalekan O. ;

Lin, Yi ;

Braunschweig, Ira ;

Hill, Brian T. ;

Timmerman, John M. ;

Deol, Abhinav ;

Reagan, Patrick M. ;

Stiff, Patrick ;

Flinn, Ian W. ;

Farooq, Umar ;

Goy, Andre ;

McSweeney, Peter A. ;

Munoz, Javier ;

Siddiqi, Tanya ;

Chavez, Julio C. ;

Herrera, Alex F. ;

Bartlett, Nancy L. ;

Wiezorek, Jeffrey S. ;

Navale, Lynn ;

Xue, Allen ;

Jiang, Yizhou ;

Bot, Adrian ;

Rossi, John M. ;

Kim, Jenny J. ;

Go, William Y. ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2019, 20 (01) :31-42

[7] Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy [J].

Maurer, Matthew J. ;

Ghesquieres, Herve ;

Jais, Jean-Philippe ;

Witzig, Thomas E. ;

Haioun, Corinne ;

Thompson, Carrie A. ;

Delarue, Richard ;

Micallef, Ivana N. ;

Peyrade, Frederic ;

Macon, William R. ;

Molina, Thierry Jo ;

Ketterer, Nicolas ;

Syrbu, Sergei I. ;

Fitoussi, Olivier ;

Kurtin, Paul J. ;

Allmer, Cristine ;

Nicolas-Virelizier, Emmanuelle ;

Slager, Susan L. ;

Habermann, Thomas M. ;

Link, Brian K. ;

Salles, Gilles ;

Tilly, Herve ;

Cerhan, James R. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1066-1073

[8] Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study [J].

Salles, Gilles ;

Duell, Johannes ;

Gonzalez Barca, Eva ;

Tournilhac, Olivier ;

Jurczak, Wojciech ;

Liberati, Anna Marina ;

Nagy, Zsolt ;

Obr, Ales ;

Gaidano, Gianluca ;

Andre, Marc ;

Kalakonda, Nagesh ;

Dreyling, Martin ;

Weirather, Johannes ;

Dirnberger-Hertweck, Maren ;

Ambarkhane, Sumeet ;

Fingerle-Rowson, Gunter ;

Maddocks, Kami .

LANCET ONCOLOGY, 2020, 21 (07) :978-988

[9] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].

Schuster, Stephen J. ;

Bishop, Michael R. ;

Tam, Constantine S. ;

Waller, Edmund K. ;

Borchmann, Peter ;

McGuirk, Joseph P. ;

Jaeger, Ulrich ;

Jaglowski, Samantha ;

Andreadis, Charalambos ;

Westin, Jason R. ;

Fleury, Isabelle ;

Bachanova, Veronika ;

Foley, S. Ronan ;

Ho, P. Joy p ;

Mielke, Stephan ;

Magenau, John M. ;

Holte, Harald ;

Pantano, Serafino ;

Pacaud, Lida B. ;

Awasthi, Rakesh ;

Chu, Jufen ;

Anak, Ozlem ;

Salles, Gilles ;

Maziarz, Richard T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :45-56

[10] Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study [J].

Tilly, Herve ;

Morschhauser, Franck ;

Bartlett, Nancy L. ;

Mehta, Amitkumar ;

Salles, Gilles ;

Haioun, Corinne ;

Munoz, Javier ;

Chen, Andy I. ;

Kolibaba, Kathryn ;

Lu, Dan ;

Yan, Mark ;

Penuel, Elicia ;

Hirata, Jamie ;

Lee, Calvin ;

Sharman, Jeff P. .

LANCET ONCOLOGY, 2019, 20 (07) :998-1010

← 1 →